Skip to content
sellWeak cluster of 310b5-1 plan

Orbimed Advisors LLC sold $1.4M of SION

director at Sionna Therapeutics, Inc.. 30,953 shares at an average of $44.58, traded Feb 2, 2026, filed Feb 4, 2026.

Warning score
35
Value
$1.4M
30,953 shares
Holdings after
3,530,702
-1% from before
From 52-week low
+470%
low $7.66, close $43.65
From 52-week high
-2%
high $44.38, as of Feb 2, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $1.4M at market
    +25
  • Share of holdings sold
    Sold 0.9% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -13.0%, 3m +4.8%, 6m +14.6%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SIONOct 12, 2026 · close 4.69
Since filing Feb 4, 2026: -88.6%SPY +13.0% · excess -101.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000947871-26-000088, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 2, 2026SOpen-market sale
Common Stockindirect: See footnotes10b5-1
-1,890$44.57$84k3,559,765Feb 4, 2026
Feb 3, 2026SOpen-market sale
Common Stockindirect: See footnotes10b5-1
-29,063$44.58$1.3M3,530,702Feb 4, 2026

Related signals

Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
50Moderate
SIONsell
Sionna Therapeutics, Inc.
Ra Capital Management, L.p.
director, owner
$22M
3,448,811 shares
-50%
35Weak
SIONsell 310b5-1
Sionna Therapeutics, Inc.
Orbimed Advisors LLC
director
$3.9M
85,918 shares
-3%
35Weak
SIONsell 310b5-1
Sionna Therapeutics, Inc.
Peter A. Thompson
director
$3.9M
85,918 shares
-3%
32Weak
SIONsell 310b5-1
Sionna Therapeutics, Inc.
Jennifer Fitzpatrick
Chief Legal Officer
$447k
10,250 shares
-100%
35Weak
SIONsell 310b5-1
Sionna Therapeutics, Inc.
Orbimed Advisors LLC
director
$5.3M
115,844 shares
-4%
35Weak
SIONsell 310b5-1
Sionna Therapeutics, Inc.
Peter A. Thompson
director
$5.3M
115,844 shares
-4%
3Weak
SIONsell 210b5-1
Sionna Therapeutics, Inc.
Orbimed Advisors LLC
director
$4,493
101 shares
-0%
3Weak
SIONsell 210b5-1
Sionna Therapeutics, Inc.
Peter A. Thompson
director
$4,493
101 shares
-0%
28Weak
SIONsell 210b5-1
Sionna Therapeutics, Inc.
Orbimed Advisors LLC
director
$13M
292,952 shares
-10%
28Weak
SIONsell 210b5-1
Sionna Therapeutics, Inc.
Peter A. Thompson
director
$13M
292,952 shares
-10%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Orbimed Advisors LLC sold $1.4M of SION | InsiderTell